Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.

NCT00933517 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Pathological Response Rate

Interventions

DRUG: vectibix
DRUG: fluorouracile
DRUG: Epirubicine
DRUG: cyclophosphamide
DRUG: docetaxel

Sponsor

Centre Jean Perrin